Lung transplant recipients receiving voriconazole and skin squamous cell carcinoma risk in Australia

by Kong, D.C.M, Kotsimbos, T., Levvey, B., Morrissey, O., Neoh, C.F, Slavin, M.A, Snell, G.I, Stewart, K.
Published 2014

Squamous cell carcinoma of the skin and voriconazole therapy in lung transplant recipients: A case series

by Kong, D.C.M, Levvey, B., Morrissey, C.O, Neoh, C.F, Slavin, M.A, Snell, G.I, Stewart, K.
Published 2017

Clinical effectiveness of early posaconazole suspension pre-emptive therapy in lung transplant recipients: The Alfred's experience

by Ivulich, S., Jeong, W., Kong, D.C.M, Levvey, B.J, Neoh, C.F, Orla Morrissey, C., Slavin, M.A, Snell, G.I, Westall, G.P
Published 2017

Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: Factors affecting trough plasma concentrations

by Ivulich, S., Jeong, W., Kong, D.C.M, Levvey, B.J, Neoh, C.F, Orla Morrissey, C., Slavin, M.A, Snell, G.I, Westall, G.P, Wolfe, R.
Published 2018

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains

by Case, J.B, Chong, Z., Corti, D., Crowe, J.E., Jr, Dang, H.V, Diamond, M.S, Droit, L., Errico, J.M, Esser, M.T, Fremont, D.H, Guarino, B., Halfmann, P.J, Handley, S.A, Jung, A., Kawaoka, Y., Loo, Y.-M, Mackin, S., Madden, E.A, Purcell, L.A, Ren, K., Rosenthal, K., Schmid, M.A, Snell, G., Virgin, H.W, Whitener, B.
Published 2022